Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00023933 · ClinicalTrials.gov registry record · Phase 1
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer
A Phase 1 study of Adenocarcinoma of the Rectum and Recurrent Colon Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT00023933 is a Phase 1 study of Adenocarcinoma of the Rectum and Recurrent Colon Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 15 participants, below the 910-participant average among 11 other Adenocarcinoma of the Rectum trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00023933, a Phase 1 study of Adenocarcinoma of the Rectum and Recurrent Colon Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase I trial to study the effectiveness of radiolabeled monoclonal antibody therapy in treating patients who have recurrent or persistent metastatic colorectal cancer. Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. Radiolabeled monoclonal antibody therapy may be effective treatment for colorectal cancer
Conditions Studied
Interventions
- DRUG iodine I 131 monoclonal antibody CC49-deltaCH2
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2001-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00023933
The ClinicalTrials.gov registry entry for NCT00023933 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 910-participant average among 11 other Adenocarcinoma of the Rectum trials with a reported enrollment target (98% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Adenocarcinoma of the Rectum appearing as the primary indexed condition, and to 1 intervention - of which iodine I 131 monoclonal antibody CC49-deltaCH2 is the first listed.
NCT00023933 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT00023933 about?
NCT00023933 is a clinical study titled "Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer". Phase I trial to study the effectiveness of radiolabeled monoclonal antibody therapy in treating patients who have recurrent or persistent metastatic colorectal cancer. Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells...
What is the current status of trial NCT00023933?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2001-10.
What conditions does trial NCT00023933 study?
This clinical trial studies the following conditions: Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Adenocarcinoma of the Colon, Stage IV Colon Cancer.
What interventions are being tested in trial NCT00023933?
The interventions under investigation include: iodine I 131 monoclonal antibody CC49-deltaCH2 (DRUG).
Who is sponsoring clinical trial NCT00023933?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00023933 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenocarcinoma of the Rectum
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
COMPLETED · Phase 1
-
Resveratrol in Treating Patients With Colorectal Cancer That Can Be Removed By Surgery
COMPLETED · Phase 1
-
Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum
COMPLETED · Phase 1
-
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
COMPLETED · Phase 1
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
-
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.